Introduction {#sec1-1}
============

Coronary artery bypass graft surgery (CABG) is a widely used treatment option for the revascularization of stenotic coronary arteries. Saphenous venous and arterial grafts are commonly used in CABG. Patency rates of saphenous vein graft (SVG) is relatively low, and 10-year patency rate for SVG was reported to be 61% ([@ref1]).

Platelets are known to play a role in atherosclerosis ([@ref2]). Also, previous studies demonstrated the role of platelets in saphenous vein graft disease (SVGD). It was shown that high mean platelet volume, platelet distribution width, plateletcrit, and platelet count were associated with SVGD ([@ref3]-[@ref5]). Lymphocytes were also shown to play role in the chronic inflammation of atherosclerosis ([@ref6]), and a histopathological study demonstrated that lymphocytes were associated with SVGD ([@ref7]).

Platelet to lymphocyte ratio (PLR) has been defined as a new prognostic marker in coronary artery disease (CAD). Increased PLR has been demonstrated to be associated with adverse outcomes and low left ventricular function in patients with acute coronary syndrome (ACS) ([@ref8], [@ref9]). A high PLR correlated with in-hospital mortality in patients with ST-elevated myocardial infarction ([@ref10], [@ref11]), severity of CAD ([@ref12]), and no reflow in patients with ST-segment elevation myocardial infarction ([@ref13]). However, no studies till date have investigated PLR in SVGD.

In this study, we aimed to investigate the predictive value of PLR in SVGD patients with stable angina pectoris (SAP).

Methods {#sec1-2}
=======

Patients {#sec2-1}
--------

After gaining approval for the study protocol by local Ethics Committee of our hospital, we retrospectively analyzed the electronic patient record system of our hospital and found 7586 patients who underwent coronary angiography due to various reasons in our clinic between January 2008 and April 2014. Among them, 455 cases with SVG that fulfilled the inclusion criteria were included in the study. There were 210 patients with SVGD and 245 patients without SVGD. There were 283 (62.2%) male patients. The mean age of the patients was 68.45±10.08 years ([Table 1](#T1){ref-type="table"}).

###### 

Baseline clinical characteristics of patients with or without saphenous vein graft disease, and the comparison of the groups for parameters that were studied (univariate analysis)

                                                            SVGD positive n=210 (46.2%)   SVGD negative n=245 (53.8%)   Total n=455 (100%)                        P value
  -------------------------------------- ------------------ ----------------------------- ----------------------------- ----------------------------------------- ---------
  Age, mean±SD                           67±11              69±9                          68±10                         0.518                                     
  Gender                                 Male, n,%          136 (64.7%)                   147 (60%)                     283 (62.2%)                               0.078
                                         Female, n %        74 (35.3%)                    98 (40%)                      172 (37.8%)                               0.215
  LVEF, %, mean±SD                       55±5               57±5                          56±6                          0.143                                     
  Hb, gr/dL, median (IQR)                13.7 (12.5-14.6)   13.4 (13-14)                  13.6 (13-14.40)               0.12                                      
  WBC count/μL, mean±SD                  9206±3403          8864±4160                     9022±3829                     0.041[\*](#t2f1){ref-type="table-fn"}     
  Neutrophil count,/μL, mean±SD          6780±3257          5967±3941                     6342±3660                     0.16                                      
  Platelet count, x109/L, median (IQR)   236 (197-275)      226 (148-258)                 226 (183-267)                 \<0.001[\*](#t2f1){ref-type="table-fn"}   
  Lymphocyte count/μL, mean±SD           1526±658           2019±806                      1792±780                      \<0.001[\*](#t2f1){ref-type="table-fn"}   
  PLR, mean±SD                           179±68             119±45                        147±64                        \<0.001[\*](#t2f1){ref-type="table-fn"}   
  Creatinine, mg/dL, mean±SD             0.99±0.31          1.08±0.31                     1.04±0.31                     0.657                                     
  Na, mEq/L, mean±SD                     138±3.4            139±3.3                       139±3.4                       0.692                                     
  Total cholesterol, g/dL median (IQR)   183 (147-214)      180 (145-203)                 180 (147-206)                 0.784                                     
  LDL, g/dL, mean±SD                     112±38             108±35                        110±36                        0.624                                     
  HDL, g/dL, mean±SD                     37±14              40±9                          39±12                         0.006[\*](#t1f1){ref-type="table-fn"}     
  ALT, U/L, median (IQR)                 21 (17-34)         17 (13-24)                    19 (14-27)                    \<0.001[\*](#t1f1){ref-type="table-fn"}   
  TSH, ıu/mL, mean±SD                    2.2±0.4            2.1±0.7                       2.1±0.8                       0.588                                     
  GGT, U/L, median (IQR)                 26 (15-44)         28 (16-35)                    27 (16-44)                    0.871                                     

ALT - alanine aminotransferase; GGT - gamma glutamyl transferase; HDL - high density lipoprotein; IQR - interquartile range; LDL - low density lipoprotein; LVEF - left ventricular ejection fraction; PLR - platelet to lymphocyte ratio; SD - standard deviation; SVGD - saphenous vein graft disease; TSH - thyroid stimulating hormone; WBC - white blood cell.

statistically significant

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Inclusion criteria were the presence of a previous coronary artery bypass graft (CABG) surgery at least 1 year ago, SVG-use during CABG, and the presence of SAP. The exclusion criteria were the presence of ACS, decompensated heart failure, atrial fibrillation, congenital valvular disease, idiopathic dilated or hypertrophic cardiomyopathy, congenital heart disease, renal failure (serum creatinine\>2.0 mg/dL), severe hepatic disease, malignant neoplasms, infection, and inflammatory diseases.

Data collection {#sec2-3}
---------------

All patients were hospitalized and underwent coronary angiography and echocardiography. Coronary angiography was performed according to the Judkins technique. An aortic root angiography was performed, and at least two planes were obtained for all SVG images. At least one SVG with ≥50% stenosis was defined as SVGD, and the patients were divided into two groups based on the presence or absence of SVGD.

Transthoracic echocardiography was performed within 72 h of the patients' admission to the hospital. Left ventricular ejection fraction (LVEF) was calculated by the Simpson's method.

Peripheral venous blood samples of the patients were obtained on their admission to the inpatient ward. An automated blood cell counter (Beckman Coulter analyzer, California, USA) was used for measuring complete blood count parameters. Blood biochemistry parameters levels that were measured were: creatinine, Na, alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), total cholesterol, high-density lipoprotein (HDL), low- density lipoprotein (LDL), gamma-glutamyl transferase (GGT), and thyroid stimulating hormone (TSH).

Statistical analysis {#sec2-4}
--------------------

SPSS 22.0 statistical package program (SPSS Inc. Chicago, IL, USA) was used to perform all data analyses. Kolmogorov-Smirnov test was used to analyze the distribution pattern. Continuous data were presented as median and interquartile range or mean+standard deviation. The effects of different variables on SVGD were computed in univariate logistic regression analysis. The variables included were age, gender, LVEF, hemoglobin, WBC, neutrophil, lymphocyte and platelet counts, PLR, creatinine, Na, total cholesterol, LDL, HDL, ALT, TSH, and GGT.

Variables that had an unadjusted p value of \<0.10 in logistic regression analysis were identified as potential risk markers and then included in the full model. We eliminated potential risk markers with likelihood ratio tests with reduced model using stepwise multivariate logistic regression analyses. The variables found to be significant in univariate logistic regression analysis were considered as potential risk markers and included in multivariate regression analysis. A p value of \<0.05 was considered statistically significant with a confidence interval of 95%. The receiver operating characteristics (ROC) curve was used to show the sensitivity and specificity of PLR, and the optimal cut-off value for predicting SVGD.

Results {#sec1-3}
=======

There were 210 (46.2%) patients with SVGD (mean age, 67.40±11.15 years, 65% males), and 245 (53.8%) patients without SVGD (mean age, 69.36±9.10 years, 60% males). Baseline characteristics of the patients and comparison of the studied parameters with relation to the presence of SVGD are presented in [Table 1](#T1){ref-type="table"}. There were no differences between the two groups for LVEF, age, gender, neutrophil count, hemoglobin levels, total cholesterol, Na, creatinine, LDL, TSH, or GGT. However, ALT, white blood cell (WBC) count, HDL, PLR, and lymphocyte count were significantly correlated with SVGD. Multivariate regression analysis model showed that HDL levels (b=0.945, 95% CI 0.924-0.926, p\<0.001) and PLR (b=1.032, 95% CI 1.019-1.045, p\<0.001) were significantly correlated with the patency of the vein graft ([Table 2](#T2){ref-type="table"}). It was found that patients with SVGD had higher PLRs compared to those without SVGD ([Fig.1](#F1){ref-type="fig"}).

###### 

Multiple logistic regression analysis showing independent predictors of saphenous vein graft disease

                                                                         95% Confidence interval   
  -------------------- ----------------------------------------- ------- ------------------------- -------
  Lymphocyte/μL        0.243                                     1.001   1                         1.001
  WBC/μL               0.073                                     0.946   0.913                     0.977
  Platelet, x10^9^/L   0.068                                     1       1                         1
  PLR                  \<0.001[\*](#t2f1){ref-type="table-fn"}   1.032   1.019                     1.045
  HDL, g/dL            \<0.001[\*](#t2f1){ref-type="table-fn"}   0.945   0.924                     0.966
  ALT, U/L             0.193                                     1.063   0.97                      1.165

ALT - alanine aminotransferase; HDL - high density lipoprotein; PLR - platelet-to-lymphocyte ratio; WBC - white blood cell,

Statistically significant.

![The levels of platelet to lymphocyte ratio in patients with and without saphenous vein graft disease\
PLR - platelet to lymphocyte ratio](AJC-16-349-g001){#F1}

Finally, ROC analysis was performed to determine the cut-off value of PLR to predict SVGD. The cut-off value of PLR on admission to predict SVGD in all study population was 147, with a sensitivity of 75.2% and a specificity of 73.9% (area under curve=0.800, 95% CI 0.75-0.84, p\<0.001; [Fig. 2](#F2){ref-type="fig"}).

![The receiver operating characteristic (ROC) curve of platelet to lymphocyte ratio for the prediction of saphenous vein graft disease](AJC-16-349-g002){#F2}

The patients were divided into two groups on the basis of a PLR level cut-off value of 147. WBC, neutrophil counts, and female gender were significantly higher in the group with higher PLR ([Table 3](#T3){ref-type="table"}).

###### 

Clinical characteristics of the study patients according to the cut-off level of platelet lymphocyte ratio

                                                         PLR\<147 (283) n (%)   PLR ≥147 (172) n (%)                      *P*
  ----------------------------------- ------------------ ---------------------- ----------------------------------------- ---------------------------------------
  Gender                                Female, n, %     92 (32.5%)             80 (46.5%)                                0.013[\*](#t3f1){ref-type="table-fn"}
                                        Male, n, %       191 (67.5%)            92 (53.5%)                                0.367
  Age, mean±SD                        67±8               68±10                  0.323                                     
  LVEF, %, mean±SD                    56±6               55±5                   0.07                                      
  WBC count/μL, mean±SD               8621±2315          9440±4914              0.025[\*](#t3f1){ref-type="table-fn"}     
  Hemoglobin, g/dL, median (IQR)      13.6 (12.3-13.9)   13.5 (12-13.7)         0.286                                     
  Neutrophil count/μL, mean±SD        5030 (3850-6550)   5950 (4580-7240)       \<0.001[\*](#t3f1){ref-type="table-fn"}   
  Total cholesterol, mg/dL, mean±SD   180±45             178±37                 0.204                                     
  LDL, mg/dL, mean±SD                 118±39             112±31                 0.37                                      
  HDL, mg/dL, mean±SD                 37±13              34±12                  0.082                                     
  TSH, ıu/mL, mean±SD                 1.89±0.92          1.73±0.81              0.115                                     

HDL - high density lipoprotein; LDL - low density lipoprotein; LVEF - left ventricular ejection fraction; PLR - platelet to lymphocyte ratio; TSH - thyroid stimulating hormone; WBC - white blood cell;

Statistically significant

Discussion {#sec1-4}
==========

In this study, we demonstrated that PLR, an easily available and inexpensive test, provided relevant information regarding the presence of SVGD in patients with SAP. To our knowledge, this is the first study in literature indicating PLR as an independent marker in SVGD.

The effectiveness of CABG is hindered by the obstruction of SVG after surgery. The causes of SVG failure differ according to the time period after surgery. Thrombosis is the dominant factor in graft failure in the first month after CABG, intimal hyperplasia between 1 and 12 months, and atherosclerosis is the main pathogenic insult to venous graft failure 12 months after surgery ([@ref14]). We included patients who had CABG \>1 year ago in our study to minimize the graft failure factors related to the surgery itself.

Histopathologically, atheroma plaque has a small lipid core with a thick fibrous cap in chronic SAP, low rupture risk, narrows the arterial lumen, and produces symptoms ([@ref15]). On the other hand, it was shown that the saphenous vein graft atheroma contained more foam and inflammatory cells including multinucleate giant cells compared to the native coronary atheroma ([@ref16]). These findings indicate that inflammation plays a role in SVDG, similar to native CAD.

Various studies investigated the inflammatory and hemostatic biomarkers in SAP. An inflammatory biological profile, including CRP, fibrinogen, and von Willebrand factor, distinguished patients with previous multiple acute coronary events from those with long-standing stable angina and predicted acute coronary instability ([@ref17]). On the other hand, a large population-based observational study conducted in initially asymptomatic middle-aged men indicated that higher circulating levels of hs-CRP, ICAM1, interleukin 6, and interleukin 18 were equally predictive of SA and ACS, after adjustment for traditional risk factors ([@ref18]). In a recent study, Açar et al. ([@ref8]) showed that PLR was significantly higher in patients with poor coronary collateral circulation compared to those with good coronary collateral circulation (patients with SAP and chronic total occlusion). However, no studies till date have investigated PLR as a marker in SVGD.

Ongoing inflammatory conditions lead to increased proliferation in the megakaryocytic series and relative thrombocytosis ([@ref19]). Previous studies demonstrated the relationship of adverse cardiovascular outcomes with both increased platelet and decreased lymphocyte counts ([@ref20]-[@ref22]). In addition, the diagnostic usefulness of low lymphocyte count was shown in patients with myocardial infarction, and its prognostic utility was demonstrated in patients with CAD ([@ref23], [@ref24]). In our study, we found higher platelet and lower lymphocyte counts in patients with SVGD and SAP when compared to those who had SAP after CABG, in the absence of SVGD. Our results indicated that high platelet and low lymphocyte counts might indicate poor outcome after CABG, in favor of SVGD.

PLR has the advantage of reflecting both activated coagulation and inflammatory pathways. In addition, PLR may be superior to individual platelet or lymphocyte counts in predicting impaired reperfusion ([@ref25]). Kurtul et al. ([@ref26]) showed that PLR was closely related to the severity of atherosclerosis. In another study, Azab et al. ([@ref9]) revealed that adverse cardiovascular outcome in non-ST-segment elevation myocardial infarction was significantly associated with higher PLR. In our study, we investigated PLR as a marker in SVGD, for the first time in the literature, and found high PLR in patients with SVGD. Our results indicate that high PLR may be a poor prognostic factor for the development of SVGD after CABG, as it is shown to be associated with the adverse outcomes after ST-segment elevation myocardial infarction ([@ref10], [@ref11], [@ref13]).

Significanly higher HDL levels in patients without SVGD may be regarded as an expected finding. However, high WBC counts in SVGD patients may be incidental because we excluded patients with infection and inflammatory diseases. The same is true for higher ALT levels found in the same group.

Study limitations {#sec1-5}
=================

Our study has some limitations that must be taken into account when evaluating the results. First, previous medical treatment options were not clearly indicated due to the retrospective nature of our study. The comorbidities of the patients, including diabetes mellitus and hypertension, cannot be determined either due to the same reason. In addition, PLR was not compared with other inflammatory markers, such as CRP, fibrinogen, or myeloperoxidase, because of the retrospective nature of our study. As a result of these limitations, our results may not apply to all SAP patients after CABG.

Conclusion {#sec1-6}
==========

We found significantly higher PLR in patients with SVGD and SAP compared to those without SVGD. PLR may be used in daily clinical practice to predict SVGD because it is a quickly accessible, widely used, and inexpensive test. Further prospective trials would better identify the clinical significance of PLR in patients with SVGD and SAP.
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